Oramed Historical Financial Ratios
| ORMP Stock | USD 2.37 0.02 0.85% |
Oramed Pharmaceuticals is promptly reporting on over 77 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 191 will help investors to properly organize and evaluate Oramed Pharmaceuticals financial condition quickly.
Oramed |
About Oramed Financial Ratios Analysis
Oramed PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Oramed Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Oramed financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Oramed Pharmaceuticals history.
Oramed Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Oramed Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Oramed Pharmaceuticals sales, a figure that is much harder to manipulate than other Oramed Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Oramed Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.At this time, Oramed Pharmaceuticals' EV To Sales is relatively stable compared to the past year. As of 11/27/2024, Payables Turnover is likely to grow to 0.21, while Operating Cash Flow Per Share is likely to drop (0.86).
| 2023 | 2024 (projected) | Graham Number | 8.29 | 8.7 | Receivables Turnover | 1.88 | 0.98 |
Oramed Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Oramed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oramed Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 21.44 | 26.44 | 207.28 | 173.56 | 156.21 | 164.02 | |
| Ptb Ratio | 2.99 | 2.18 | 4.84 | 3.09 | 2.78 | 2.92 | |
| Book Value Per Share | 1.11 | 1.6 | 4.09 | 3.88 | 3.49 | 3.66 | |
| Free Cash Flow Yield | (0.22) | (0.17) | (0.0385) | (0.0606) | (0.0697) | (0.0731) | |
| Operating Cash Flow Per Share | (0.98) | (0.74) | (0.61) | (0.72) | (0.82) | (0.86) | |
| Stock Based Compensation To Revenue | 0.3 | 0.43 | 1.0 | 4.26 | 3.83 | 4.02 | |
| Capex To Depreciation | 1.88 | 11.71 | 4.87 | 8.55 | 7.7 | 8.08 | |
| Pb Ratio | 2.99 | 2.18 | 4.84 | 3.09 | 2.78 | 2.92 | |
| Ev To Sales | 20.21 | 19.35 | 178.9 | 158.92 | 143.03 | 150.18 | |
| Free Cash Flow Per Share | (0.74) | (0.61) | (0.76) | (0.73) | (0.84) | (0.8) | |
| Roic | (1.09) | (0.36) | (0.18) | (0.27) | (0.24) | (0.25) | |
| Net Income Per Share | (0.82) | (0.56) | (0.78) | (0.97) | (1.11) | (1.17) | |
| Sales General And Administrative To Revenue | 1.38 | 1.56 | 2.2 | 5.11 | 5.88 | 3.65 | |
| Research And Ddevelopement To Revenue | 5.0 | 3.78 | 7.77 | 10.23 | 11.76 | 7.69 | |
| Capex To Revenue | 0.002042 | 0.005549 | 0.0303 | 0.14 | 0.18 | 0.17 | |
| Cash Per Share | 1.85 | 1.94 | 3.31 | 3.99 | 3.59 | 3.77 | |
| Pocfratio | (4.48) | (5.76) | (26.45) | (16.8) | (15.12) | (15.88) | |
| Capex To Operating Cash Flow | (0.001159) | (0.006592) | (0.0177) | (0.0178) | (0.016) | (0.0152) | |
| Pfcf Ratio | (4.47) | (5.72) | (25.99) | (16.51) | (14.86) | (15.6) | |
| Income Quality | 1.15 | 0.9 | 1.08 | 0.92 | 0.74 | 0.67 | |
| Roe | (0.74) | (0.35) | (0.19) | (0.25) | (0.22) | (0.24) | |
| Pe Ratio | (5.79) | (4.04) | (6.23) | (25.19) | (11.18) | (11.74) | |
| Ev To Free Cash Flow | (4.22) | (4.19) | (22.43) | (15.12) | (13.61) | (14.29) | |
| Earnings Yield | (0.17) | (0.25) | (0.16) | (0.0397) | (0.0926) | (0.0972) | |
| Net Debt To E B I T D A | 0.23 | 1.7 | 3.06 | 1.07 | 0.96 | 0.56 | |
| Current Ratio | 6.28 | 8.93 | 14.27 | 27.34 | 24.61 | 25.84 | |
| Tangible Book Value Per Share | 1.11 | 1.6 | 4.09 | 3.88 | 3.49 | 3.66 | |
| Graham Number | 4.53 | 4.49 | 8.45 | 9.21 | 8.29 | 8.7 | |
| Shareholders Equity Per Share | 1.11 | 1.6 | 4.07 | 3.89 | 3.5 | 3.68 | |
| Debt To Equity | (0.29) | 0.002281 | 0.004604 | 0.005889 | 0.006772 | 0.007111 | |
| Capex Per Share | 8.59E-4 | 0.003994 | 0.0132 | 0.0127 | 0.0114 | 0.012 |
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Oramed Stock
| 0.61 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.42 | GILD | Gilead Sciences | PairCorr |
| 0.42 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.